This seven-part live CME series brings together leading experts in the field to target gaps in knowledge of Hidradenitis Suppurativa diagnosis and treatment. The curriculum provides practical tips on diagnosis, pathogenesis, assessment, and comprehensive management for clinicians who treat patients with HS. Program faculty provide the latest insights on currently available and innovative approaches to treatment and care.
- Describe the range of current treatment guidelines for HS
- Compare the emerging knowledge of HS pathogenesis with current therapeutic approaches
- Review the variety of novel pipeline treatments for HS currently under development
- Discuss the way in which these pipeline treatments may influence HS guidelines over the next 5 years
Disclosure of Conflicts of Interest
Your CE Source ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, Your CE Source identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Your CE Source to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Your CE Source is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
|Name of Faculty||Reported Financial Relationship|
|John Frew, MBBS, FACD||
Research Grant- Sun Pharma
Advisory Board- Pfizer; Advisory Board- Boeringher INgelheim; Advisory Board-Janssen; Advisory Board-LEO Pharma;Advisory Board- Kyowa Kirin
|Name of Editor / Scientific Reviewer||Reported Financial Relationship|
|Joslyn Kirby, MD, MS, MEd||
Consulting Fees (e.g. Advisory Board)
AbbVie, ChemoCentryx, Incyte, InflaRx, Janssen, Novartis, UCB
The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:
|Name of Content Manager||Reported Financial Relationship|
|Venita Sivamani, Planner||LearnHealth founder and shareholder|
|Planners at Your CE Source||No financial relationships to disclose|
All other faculty, planner and/or content managers have nothing to disclose nor do they have any vested interests or affiliations. All conflicts of interest have been resolved.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Your CE Source and LearnHealth. Your CE Source is accredited by the ACCME to provide continuing medical education for physicians.
Your CE Source designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CE activity provides 1 contact hour of continuing nursing education. Your CE Source is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 16031.
Method of Participation
Participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the post test by recording the best answer to each quiz question, and 4) complete the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. Statements of credit will be available once the evaluation form is completed.
The content, views, and opinions presented in this educational activity are those of the faculty/authors and do not necessarily reflect those of Your CE Source and/or LearnHealth. The faculty/authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Learners are required to adhere to the privacy and confidentiality policy as it relates to the CE activities provided on the Internet. Please see the policy at https://www.yourcesource.org